Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody.
Jianqun KouPhillip R MusichBen StaalLiang KangYuan QinZhi Q YaoBoheng ZhangWeizhong WuAngela TamAlan HuangHuai-Xiang HaoGeorge F Vande WoudeQian XiePublished in: Journal of translational medicine (2018)
Our results demonstrate that METamp and HGF-autocrine activation favor different molecular mechanisms. While combining MET TKIs and ATM inhibitors may enhance the efficacy for treating tumors harboring METamp, a combined inhibition of MET and angiogenesis pathways may improve the therapeutic efficacy against HGF-autocrine tumors.